Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AST-3424 in AKR1C3-positive advanced hepatocellular carcinoma and other malignant tumors
CTR20191399Phase 2Active
- Sponsor
- Accendatech
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of odafosfamide in hepatocellular carcinoma (HCC), T-cell leukemia, peripheral T-cell lymphoma (PTCL), prostate cancer (PCa), bladder cancer, sponsored by Accendatech. Started Jul 2022; status: active.
02
Drugs
odafosfamide
03
Conditions
hepatocellular carcinoma (HCC)T-cell leukemiaperipheral T-cell lymphoma (PTCL)prostate cancer (PCa)bladder cancer
Beyond the preview
Go deeper on CTR20191399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191399.